Lv32
352 积分 2026-06-26 加入
Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties
1天前
已完结
Cannabidiol Alleviates LPS-Induced Depressive-Like Behaviors Via Improving Mitochondria Function
1个月前
已完结
Quizartinib inhibits necroptosis by targeting receptor‐interacting serine/threonine protein kinase 1
1个月前
已完结
Quizartinib inhibits necroptosis by targeting receptor‐interacting serine/threonine protein kinase 1
1个月前
已完结
A comprehensive meta-analysis on the efficacy of emotionally focused couple therapy
2个月前
已完结
Arthroscopic dynamic reconstruction of supraspinatus tendon with autologous fascia lata combined with artificial ligament for irreparable massive rotator cuff tears
1个月前
已采纳
LBP-022-YI Single-dose of a novel monoclonal anti-HBV antibody (HepB mAb19) demonstrates sustained HBsAg suppression beyond 48 weeks: interim results from first-in-human phase I RUHBV1 and SAMBA trials
1个月前
已采纳
Exploring the impacts of topography on characteristics of urban road network: A global empirical analysis
1个月前
已采纳
Can public R&D subsidy facilitate firms’ exploratory innovation? The heterogeneous effects between central and local subsidy programs
1个月前
已驳回
Navigating the landscape: A comprehensive overview of computational approaches in therapeutic antibody design and analysis
1个月前
已采纳
Breaking oil–water emulsions co-stabilized by CaCO3 solids and natural stabilizers: efficient strategy and mechanisms
1个月前
已采纳
Nonstationary 13C metabolic flux analysis reveals cryptic phenylacetic acid catabolism in glucose-limited Penicillium chrysogenum chemostat cultures
1个月前
已采纳
Signal-driven interplay between lipid peroxidation and ferroptosis orchestrates osteoarthritis degeneration
1个月前
已采纳
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial
2个月前
已采纳
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial
2个月前
已采纳
皖公网安备34019202002308
